Loading clinical trials...
Loading clinical trials...
A Phase 2 Study of MK-2206 in Patients With Relapsed or Refractory Diffuse Large-B Cell Lymphoma
Conditions
Interventions
Akt Inhibitor MK2206
Laboratory Biomarker Analysis
+1 more
Locations
9
France
Hopitaux de Paris
Vellefaux, Paris, France
Institut Bergonie Cancer Center
Bordeaux, France
Henri Mondor University-Hospital Center
Créteil, France
Hospital Claude Huriez Chru
Lille, France
Centre Leon Berard
Lyon, France
Institut Paoli Calmettes
Marseille, France
Start Date
December 1, 2011
Primary Completion Date
June 1, 2013
Completion Date
June 1, 2014
Last Updated
September 28, 2017
NCT05006716
NCT06026319
NCT07368270
NCT07255963
NCT05940272
NCT06352242
Lead Sponsor
National Cancer Institute (NCI)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions